Attached files

file filename
10-K - 10-K - CTI BIOPHARMA CORPcti10k12312015document.htm
EX-31.1 - EXHIBIT 31.1 - CTI BIOPHARMA CORPexhibit311sect302certceo.htm
EX-31.2 - EXHIBIT 31.2 - CTI BIOPHARMA CORPexhibit312sect302certcfo.htm
EX-10.36 - EXHIBIT 10.36 - CTI BIOPHARMA CORPexhibit1036ltipamendmentjb.htm
EX-12.1 - EXHIBIT 12.1 - CTI BIOPHARMA CORPexhibit121ratioofearningst.htm
EX-10.11 - EXHIBIT 10.11 - CTI BIOPHARMA CORPexhibit1011smtseveranceagr.htm
EX-10.37 - EXHIBIT 10.37 - CTI BIOPHARMA CORPexhibit1037ltipamendmentmp.htm
EX-23.1 - EXHIBIT 23.1 - CTI BIOPHARMA CORPexhibit231accountingfirmco.htm
EX-10.5 - EXHIBIT 10.5 - CTI BIOPHARMA CORPexhibit105amendment3todrbi.htm
EX-21.1 - EXHIBIT 21.1 - CTI BIOPHARMA CORPexhibit21110kfy2015subsidi.htm
EX-10.35 - EXHIBIT 10.35 - CTI BIOPHARMA CORPexhibit1035seeleyltipaward.htm
EX-10.12 - EXHIBIT 10.12 - CTI BIOPHARMA CORPexhibit1012directorcompens.htm

Exhibit 32


CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002

I, James A. Bianco, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that the Annual Report of CTI BioPharma Corp. on Form 10‑K for the fiscal year ended December 31, 2015 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10‑K fairly presents in all material respects the financial condition and results of operations of CTI BioPharma Corp.

A signed original of this written statement required by Section 906 has been provided to CTI BioPharma Corp. and will be retained by CTI BioPharma Corp. and furnished to the Securities and Exchange Commission or its staff upon request.


Dated: February 16, 2016
By:  /s/ James A. Bianco
 
James A. Bianco, M.D.
 
President and Chief Executive Officer



I, Louis A. Bianco, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that the Annual Report of CTI BioPharma Corp. on Form 10‑K for the fiscal year ended December 31, 2015 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10‑K fairly presents in all material respects the financial condition and results of operations of CTI BioPharma Corp.

A signed original of this written statement required by Section 906 has been provided to CTI BioPharma Corp. and will be retained by CTI BioPharma Corp. and furnished to the Securities and Exchange Commission or its staff upon request.


Dated: February 16, 2016
By:  /s/ Louis A. Bianco
 
Louis A. Bianco
 
Executive Vice President
 
Finance and Administration